Whether daily BPC-157 is safe has not been tested in people. No controlled trial has run a daily schedule, for any length of time, and published the results.
Daily schedules circulate widely on forums. They come from extrapolated animal doses and personal reports, not from human dose-finding studies. A 2026 review of BPC-157’s development describes no approved formulation, no validated dosing regimen and no completed Phase II clinical trial (PMID 42198317). That means no one has established a safe daily amount, a safe duration, or what happens with months of repeated use.
The regulatory record reflects the same gap. BPC-157 is not FDA-approved and is not on FDA’s 503A Bulks List. FDA’s Pharmacy Compounding Advisory Committee voted on July 23, 2026 to recommend it, and FDA has not acted on that vote, though since October 30, 2026 an HHS policy lets a licensed 503A pharmacy compound BPC-157 on a prescription.
How often to take any peptide, and whether to take it at all, is a decision for a licensed clinician who has reviewed your history, medications and labs.